Healthcare provider profile · identity verified

Laquinya Stipe, NP

Nurse Practitioner · GRETNA, LA · NPI 1407507494

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	346	124
Rosuvastatin Calcium	Rosuvastatin Calcium	305	103
Atorvastatin Calcium	Atorvastatin Calcium	294	114
Albuterol Sulfate Hfa	Albuterol Sulfate	197	84
Furosemide	Furosemide	188	71
Losartan Potassium	Losartan Potassium	183	69
Meloxicam	Meloxicam	180	63
Gabapentin	Gabapentin	160	64
Carvedilol	Carvedilol	147	45
Hydrochlorothiazide	Hydrochlorothiazide	142	47
Tamsulosin Hcl	Tamsulosin Hcl	138	51
Montelukast Sodium	Montelukast Sodium	136	54
Ozempic	Semaglutide	132	23
Pantoprazole Sodium	Pantoprazole Sodium	121	45
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	115	25
Metformin Hcl	Metformin Hcl	114	44
Omeprazole	Omeprazole	109	46
Levothyroxine Sodium	Levothyroxine Sodium	105	37
Metoprolol Succinate	Metoprolol Succinate	105	32
Fluticasone Propionate	Fluticasone Propionate	99	55
Tizanidine Hcl	Tizanidine Hcl	97	41
Prednisone	Prednisone	96	59
Clopidogrel	Clopidogrel Bisulfate	93	26
Hydroxyzine Hcl	Hydroxyzine Hcl	88	41
Spironolactone	Spironolactone	84	30
Diclofenac Sodium	Diclofenac Sodium	82	30
Potassium Chloride	Potassium Chloride	82	29
Escitalopram Oxalate	Escitalopram Oxalate	78	34
Trazodone Hcl	Trazodone Hcl	74	30
Triamcinolone Acetonide	Triamcinolone Acetonide	73	43
Lisinopril	Lisinopril	70	24
Memantine Hcl	Memantine Hcl	70	24
Azithromycin	Azithromycin	69	61
Jardiance	Empagliflozin	69	23
Mirtazapine	Mirtazapine	68	24
Metoprolol Tartrate	Metoprolol Tartrate	66	18
Glipizide	Glipizide	65	19
Metformin Hcl Er	Metformin Hcl	65	25
Valsartan	Valsartan	60	25
Oxybutynin Chloride Er	Oxybutynin Chloride	55	18
Allopurinol	Allopurinol	54	20
Finasteride	Finasteride	50	15
Ibuprofen	Ibuprofen	50	24
Sertraline Hcl	Sertraline Hcl	50	15
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	47	17
Methylprednisolone	Methylprednisolone	47	42
Zolpidem Tartrate	Zolpidem Tartrate	47	suppressed
Fluconazole	Fluconazole	46	23
Vitamin D2	Ergocalciferol (Vitamin D2)	46	22
Alendronate Sodium	Alendronate Sodium	45	18
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	43	19
Pravastatin Sodium	Pravastatin Sodium	42	16
Mupirocin	Mupirocin	37	32
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	12
Nifedipine Er	Nifedipine	34	suppressed
Eliquis	Apixaban	33	11
Famotidine	Famotidine	33	11
Fluoxetine Hcl	Fluoxetine Hcl	33	13
Cephalexin	Cephalexin	32	28
Donepezil Hcl	Donepezil Hcl	32	15
Spiriva Handihaler	Tiotropium Bromide	31	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	12
Glimepiride	Glimepiride	29	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	12
Promethazine Hcl	Promethazine Hcl	29	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	28	suppressed
Ipratropium Bromide	Ipratropium Bromide	28	17
Simvastatin	Simvastatin	28	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	27	suppressed
Mounjaro	Tirzepatide	27	suppressed
Alprazolam	Alprazolam	25	suppressed
Ondansetron Odt	Ondansetron	25	18
Tramadol Hcl	Tramadol Hcl	25	21
Nitrofurantoin	Nitrofurantoin Macrocrystal	24	21
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	12
Methocarbamol	Methocarbamol	23	17
Ammonium Lactate	Ammonium Lactate	22	13
Pregabalin	Pregabalin	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Nitroglycerin	Nitroglycerin	21	12
Ondansetron Hcl	Ondansetron Hcl	21	11
Buspirone Hcl	Buspirone Hcl	20	11
Bumetanide	Bumetanide	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Ofloxacin	Ofloxacin	19	17
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	19	17
Baclofen	Baclofen	18	suppressed
Torsemide	Torsemide	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Meclizine Hcl	Meclizine Hcl	16	14
Ramipril	Ramipril	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Linzess	Linaclotide	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Lactulose	Lactulose	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Bupropion Xl	Bupropion Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	11
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Methimazole	Methimazole	12	suppressed
Movantik	Naloxegol Oxalate	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error